The succesfull treatment of follicular lymphomarelaps performed by 90Y Ibritumomab tiuxetan (Zevalin)

Czech version

Authors: J. Slabý ¹; T. Kozák ¹; O. Bělohlávek ²; O. Lang ³
Authors‘ workplace: Oddělení klinické hematologie, FNKV, Praha, 2PET centrum, Nemocnice Na Homolce, Praha, 3Oddělení nukleární medicíny, FNKV, Praha ¹
Published in: Transfuze Hematol. dnes,, 2004, No. 3, p. 112-113.
Category:

Overview

Radioimmunotherapy represents the other step in specific anti-tumor therapy. 57-years old womanreceived Ytrium 90 ibritumomab tiuxetan (Zevalin) as a treatment of relaps of follicular lymphoma.Treatment was tolerated very well; it was followed by uncomplicated trombocytopenia (Gr. 3, WHOclassification) andneutropenia (Gr. 2,WHOclassification).PET-CT evaluationperformed after finishingof treatment revealed achievement of complete remission.

Key words:
radioimmunotherapy, Ytrium 90 ibritumomab tiuxetan, follicular lymphoma

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.

Labels

Haematology Internal medicine Clinical oncology

Monitoring of hematopoieticrecovery and cytotoxic activity of NK-cells after allogeneichematopoietic cell transplantation.

Myeloid sarcoma (myelosarcoma): classification, diagnosis,biologic manifestation and prognosis

Dyserythropoiesis and congenital dyserythropoietic anaemias (CDA)

Opinion Research of Blood Donors – Results of a AnonymousQuestionnaire

World apheresis registry and its potential utilization in the CzechRepublic

The production of the Blood Transfusion Service in theCzech Republic in 2003

Article was published in

Transfusion and Haematology Today

2004 Issue 3